218 related articles for article (PubMed ID: 16341237)
1. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
Issa JP
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
Fenaux P
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
[TBL] [Abstract][Full Text] [Related]
3. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
Silverman LR; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
[TBL] [Abstract][Full Text] [Related]
4. Decitabine in myelodysplastic syndromes.
Saba HI; Wijermans PW
Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
[TBL] [Abstract][Full Text] [Related]
5. Decitabine.
Daskalakis M; Blagitko-Dorfs N; Hackanson B
Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
[TBL] [Abstract][Full Text] [Related]
6. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
Kuykendall JR
Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
[TBL] [Abstract][Full Text] [Related]
7. Decitabine. MGI Pharma Inc/SuperGen Inc.
Arthur C
IDrugs; 2004 Dec; 7(12):1113-32. PubMed ID: 15599805
[TBL] [Abstract][Full Text] [Related]
8. Decitabine.
Hackanson B; Daskalakis M
Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
[TBL] [Abstract][Full Text] [Related]
9. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Lübbert M; Kuendgen A
Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
[No Abstract] [Full Text] [Related]
10. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of azacitidine: onset, duration, and treatment.
Martínez-Francés A
Adv Ther; 2011 Jun; 28 Suppl 4():1-5. PubMed ID: 21688206
[TBL] [Abstract][Full Text] [Related]
12. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
Gore SD
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238
[TBL] [Abstract][Full Text] [Related]
14. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
15. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine adverse effects in patients with myelodysplastic syndromes.
San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Yee KW; Jabbour E; Kantarjian HM; Giles FJ
Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
[TBL] [Abstract][Full Text] [Related]
18. Concise drug review: azacitidine and decitabine.
Derissen EJ; Beijnen JH; Schellens JH
Oncologist; 2013; 18(5):619-24. PubMed ID: 23671007
[TBL] [Abstract][Full Text] [Related]
19. Decitabine for acute myeloid leukemia.
Marks PW
Expert Rev Anticancer Ther; 2012 Mar; 12(3):299-305. PubMed ID: 22369322
[TBL] [Abstract][Full Text] [Related]
20. Decitabine dosage in myelodysplastic syndromes.
Giagounidis AA
Blood; 2007 Aug; 110(3):1082-3; author reply 1083. PubMed ID: 17644750
[No Abstract] [Full Text] [Related]
[Next] [New Search]
